IBI-321
- Generic Name
- IBI-321
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT05172856
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04911894
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04911881
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath